  Typ výsledku
Autor celku
Název celku(Celkem 7 zázn.)
|
|---|
| Morell Anselm, Novotna Eva, Milan Jaroslav, Danielisova Petra, Bukum Neslihan, Wsol Vladimir. Selective inhibition of aldo‑keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. Archives of Toxicology, 2021, sv. 95, s. 67–78. ISSN 0340-5761. [Článek v časopise] |
| Bukum, Neslihan. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldoketo reductase 1C3. Chemico-Biological Interactions, 2019, sv. 302, s. 101–107. ISSN 0009-2797. IF 3.407. [Článek v časopise] |
| Büküm, Neslihan, OVERCOMING DAUNORUBICIN RESISTANCE MEDIATED BY ALDO-KETO REDUCTASE 1B10. BUKUM, N., MORELL, A., NOVOTNA, E., WSOL, V., Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Czech Republic bukumn@faf.cuni.cz [Jiný výsledek] |
| Bukum Neslihan, Novotna Eva, Morell Anselm, Želazková Jana, Laštovičková Lenka, Čermáková Lucie, Portillo Ramon, Solich Petr, Wsól Vladimir, Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target for Bcr-Abl tyrosine kinase inhibitor dasatinib. [Jiný výsledek] |
| Büküm, Neslihan, Poster presentation [Jiný výsledek] |
| Büküm, Neslihan, Abstract Buparlisib [Jiný výsledek] |
| Bukum, Neslihan, Conference of the Carbonyl 2018: “19th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism” in Denver, USA, where she actively presented this project in form of a poster and a short talk, acknowledging the financial support by the Grant Agency of Charles University. [Jiný výsledek] |
